Solvonis Therapeutics plc (LON:SVNS)
0.2120
-0.0180 (-7.83%)
Jun 4, 2026, 4:35 PM GMT
Solvonis Therapeutics Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.72 | 0.76 | 0.16 | 1.64 | 0.6 |
Cash & Short-Term Investments | 1.72 | 0.76 | 0.16 | 1.64 | 0.6 |
Cash Growth | 127.21% | 388.39% | -90.55% | 174.25% | 1433.33% |
Accounts Receivable | - | - | 0.07 | 0.04 | 0.02 |
Other Receivables | 0.05 | 0.03 | 0.02 | 0.06 | 0.12 |
Receivables | 0.05 | 0.03 | 0.09 | 0.1 | 0.14 |
Inventory | - | - | 0.05 | 0.19 | - |
Prepaid Expenses | 0.05 | 0.02 | 0.02 | 0.23 | - |
Other Current Assets | 0.1 | 0.01 | - | - | - |
Total Current Assets | 1.92 | 0.82 | 0.31 | 2.16 | 0.74 |
Property, Plant & Equipment | - | - | 0.04 | 0.7 | 0.31 |
Other Intangible Assets | 5.67 | 2.09 | 2.07 | 2.07 | 2.07 |
Other Long-Term Assets | - | 0.3 | 0.01 | 0.01 | 0.01 |
Total Assets | 7.59 | 3.2 | 2.43 | 4.94 | 3.13 |
Accounts Payable | 0.41 | 0.08 | 0.16 | 0.19 | 0.84 |
Accrued Expenses | 0.07 | 0.04 | 0.09 | 0.14 | 0.52 |
Short-Term Debt | - | - | - | - | 0.96 |
Current Portion of Leases | - | - | 0.01 | 0 | - |
Current Unearned Revenue | - | - | 0.09 | 0.04 | - |
Other Current Liabilities | 0.01 | - | 0.03 | - | - |
Total Current Liabilities | 0.48 | 0.12 | 0.39 | 0.37 | 2.32 |
Long-Term Debt | 0.08 | - | - | - | - |
Long-Term Leases | - | - | 0.02 | 0.02 | - |
Other Long-Term Liabilities | 0.84 | - | - | - | - |
Total Liabilities | 1.39 | 0.12 | 0.41 | 0.39 | 2.32 |
Common Stock | 6.74 | 2.23 | 0.04 | 0.04 | 0.01 |
Additional Paid-In Capital | 10.87 | 7.36 | 7 | 7 | 0.94 |
Retained Earnings | -16.3 | -10.56 | -8.97 | -5.85 | -3.14 |
Comprehensive Income & Other | 4.87 | 4.04 | 3.95 | 3.36 | 3 |
Shareholders' Equity | 6.19 | 3.08 | 2.03 | 4.55 | 0.81 |
Total Liabilities & Equity | 7.59 | 3.2 | 2.43 | 4.94 | 3.13 |
Total Debt | 0.08 | - | 0.03 | 0.02 | 0.96 |
Net Cash (Debt) | 1.65 | 0.76 | 0.12 | 1.62 | -0.36 |
Net Cash Growth | 117.30% | 525.62% | -92.52% | - | - |
Net Cash Per Share | 0.00 | 0.00 | 0.00 | 0.02 | -0.01 |
Filing Date Shares Outstanding | 6,806 | 2,296 | 124.76 | 104.1 | 70 |
Total Common Shares Outstanding | 6,806 | 2,296 | 104.1 | 104.1 | 70 |
Working Capital | 1.44 | 0.7 | -0.07 | 1.79 | -1.58 |
Book Value Per Share | 0.00 | 0.00 | 0.02 | 0.04 | 0.01 |
Tangible Book Value | 0.52 | 1 | -0.04 | 2.49 | -1.26 |
Tangible Book Value Per Share | 0.00 | 0.00 | -0.00 | 0.02 | -0.02 |
Machinery | - | - | - | 0.94 | 0.54 |
Leasehold Improvements | - | - | - | 0.09 | - |